Goldman Sachs’s Lineage Cell Therapeutics LCTX Stock Holding History

Goldman Sachs’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.85M	Sell	1,169,427 -269,319	-19%	-$454K	﹤0.01%	4609
2025 Q4	$2.4M	Buy	1,438,746 +1,294,070	+894%	+$2.24M	﹤0.01%	4406
2025 Q3	$245K	Sell	144,676 -35,513	-20%	-$42K	﹤0.01%	5864
2025 Q2	$164K	Sell	180,189 -169,914	-49%	-$101K	﹤0.01%	5714
2025 Q1	$158K	Sell	350,103 -34,963	-9%	-$20.5K	﹤0.01%	5684
2024 Q4	$193K	Buy	385,066 +140,842	+58%	+$103K	﹤0.01%	5652
2024 Q3	$221K	Buy	244,224 +79,640	+48%	+$73.8K	﹤0.01%	5423
2024 Q2	$164K	Buy	164,584 +138,030	+520%	+$152K	﹤0.01%	5312
2024 Q1	$39.3K	Sell	26,554 -10,893	-29%	-$12.3K	﹤0.01%	5342
2023 Q4	$40.8K	Buy	37,447 +7,557	+25%	+$8.28K	﹤0.01%	5399
2023 Q3	$35.3K	Buy	29,890 +3,370	+13%	+$4.58K	﹤0.01%	5311
2023 Q2	$37.4K	Sell	26,520 -253,249	-91%	-$350K	﹤0.01%	5494
2023 Q1	$420K	Buy	279,769 +265,690	+1,887%	+$371K	﹤0.01%	4926
2022 Q4	$16.5K	Sell	14,079 -1,394	-9%	-$1.76K	﹤0.01%	5721
2022 Q3	$17K	Sell	15,473 -64,696	-81%	-$95K	﹤0.01%	5962
2022 Q2	$127K	Sell	80,169 -47,263	-37%	-$62.3K	﹤0.01%	5793
2022 Q1	$196K	Buy	127,432 +28,773	+29%	+$44.6K	﹤0.01%	5897
2021 Q4	$242K	Buy	98,659 +1,588	+2%	+$3.72K	﹤0.01%	5791
2021 Q3	$245K	Buy	97,071 +83,697	+626%	+$215K	﹤0.01%	5619
2021 Q2	$38K	Sell	13,374 -185,264	-93%	-$479K	﹤0.01%	6097
2021 Q1	$467K	Buy	+198,638	New	+$477K	﹤0.01%	5172
2020 Q3	–	Sell	-120,899	Closed	-$105K	–	5450
2020 Q2	$105K	Buy	120,899 +55,189	+84%	+$48.6K	﹤0.01%	4982
2020 Q1	$54K	Sell	65,710 -33,123	-34%	-$33K	﹤0.01%	5039
2019 Q4	$88K	Buy	98,833 +53,721	+119%	+$44.8K	﹤0.01%	5060
2019 Q3	$44K	Buy	45,112 +10,084	+29%	+$10.4K	﹤0.01%	5056
2019 Q2	$39K	Sell	35,028 -7,438	-18%	-$8.57K	﹤0.01%	5033
2019 Q1	$56K	Sell	42,466 -28,799	-40%	-$35.8K	﹤0.01%	4992
2018 Q4	$65K	Sell	71,265 -695	-1%	-$1.06K	﹤0.01%	5064
2018 Q3	$148K	Sell	71,960 -514	-0.7%	-$1.08K	﹤0.01%	5008
2018 Q2	$130K	Buy	72,474 +28,094	+63%	+$56.6K	﹤0.01%	5135
2018 Q1	$104K	Buy	44,380 +10,252	+30%	+$24K	﹤0.01%	5272
2017 Q4	$64K	Sell	34,128 -12,410	-27%	-$27.1K	﹤0.01%	5883
2017 Q3	$116K	Buy	46,538 +2,047	+5%	+$5.08K	﹤0.01%	6000
2017 Q2	$123K	Sell	44,491 -64,718	-59%	-$181K	﹤0.01%	6041
2017 Q1	$330K	Buy	109,209 +90,585	+486%	+$257K	﹤0.01%	5391
2016 Q4	$59K	Buy	18,624 +1,110	+6%	+$3.41K	﹤0.01%	6341
2016 Q3	$60K	Sell	17,514 -7,639	-30%	-$21.1K	﹤0.01%	6413
2016 Q2	$57K	Buy	25,153 +7,835	+45%	+$19.2K	﹤0.01%	6381
2016 Q1	$43K	Buy	+17,318	New	+$38.6K	﹤0.01%	6493
2015 Q4	–	Sell	-15,009	Closed	-$36K	–	7265
2015 Q3	$36K	Sell	15,009 -39,534	-72%	-$102K	﹤0.01%	6891
2015 Q2	$160K	Buy	54,543 +37,720	+224%	+$146K	﹤0.01%	6318
2015 Q1	$67K	Sell	16,823 -1,697	-9%	-$5.87K	﹤0.01%	6593
2014 Q4	$56K	Buy	+18,520	New	+$50.1K	﹤0.01%	6777
2014 Q3	–	Sell	-14,889	Closed	-$37K	–	7189
2014 Q2	$37K	Sell	14,889 -70,683	-83%	-$160K	﹤0.01%	6807
2014 Q1	$227K	Buy	85,572 +52,116	+156%	+$153K	﹤0.01%	5976
2013 Q4	$97K	Buy	33,456 +9,240	+38%	+$27.9K	﹤0.01%	6292
2013 Q3	$74K	Buy	24,216 +2,862	+13%	+$9.06K	﹤0.01%	6231
2013 Q2	$68K	Buy	+21,354	New	+$68.4K	﹤0.01%	5986

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $3.03B AUM 36.06% 1-Year Est. Return

Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return